Dolutegravir + Lamivudine + TDFTablet
HIV / Antiretroviral

Dolutegravir + Lamivudine + TDF

Dolutegravir + Lamivudine + Tenofovir DF

WHO-recommended first-line single-tablet ART regimen combining INSTI with dual NRTI backbone for treatment-naive HIV patients. Manufactured by Cipla and Hetero for global HIV program export.

Strengths

50mg + 300mg + 300mg

Packing

30 tablets/bottle

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request QuotationWhatsApp
Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Dolutegravir 50mg + Lamivudine 300mg + Tenofovir Disoproxil Fumarate 300mg
Dosage Form
Tablet
Available Strengths
50mg + 300mg + 300mg
Packing
30 tablets/bottle
Route of Administration
Oral, with or without food
Dosage
One tablet once daily; take at the same time each day
Indications
HIV-1 infection in adults and adolescents weighing >=25kg as first-line therapy
Country of Origin
India (WHO-GMP Certified)
Storage
Store below 30°C, protect from moisture
Shelf Life
24 months
Side Effects
Insomnia, headache, nausea, diarrhea, fatigue, renal impairment (TDF component)
Precautions
Monitor renal function (TDF nephrotoxicity); HBV flare on discontinuation (lamivudine); weight gain reported with DTG; neural tube defect risk — discuss with women of childbearing potential

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Efavirenz 600mgTablet

Efavirenz 600mg

Efavirenz

Second-generation NNRTI that allosterically inhibits HIV-1 reverse transcriptase, a backbone of PEPFAR-supported first-line HIV treatment in sub-Saharan Africa and Southeast Asia. Available in the landmark fixed-dose combination TDF/3TC/EFV (Atripla/generic), which transformed HIV care globally with a once-daily single-pill regimen.

50mg / 200mg / 600mg
Lopinavir + Ritonavir 200/50mgTablet

Lopinavir + Ritonavir 200/50mg

Lopinavir + Ritonavir

Fixed-dose combination where sub-therapeutic ritonavir inhibits CYP3A4 to dramatically boost lopinavir plasma levels, achieving reliable viral suppression without food restrictions for the tablet formulation. Widely used in pediatric HIV as oral solution and an affordable PEPFAR-supported generic in resource-limited settings globally.

200mg + 50mg (tablet); 80mg + 20mg/mL (solution)
Atazanavir + Ritonavir 300/100mgCapsule

Atazanavir + Ritonavir 300/100mg

Atazanavir + Ritonavir

Ritonavir-boosted azapeptide protease inhibitor distinguished by its unique pharmacokinetic characteristic of causing benign indirect hyperbilirubinemia (marker of absorption), once-daily dosing convenience, and a significantly more favorable lipid profile than lopinavir/ritonavir. Preferred second-line choice in resource-limited settings and in patients with dyslipidemia or cardiovascular risk.

150mg / 200mg / 300mg (atazanavir); 100mg (ritonavir)

Need bulk pricing for Dolutegravir + Lamivudine + TDF?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote